文献速递类风湿关节炎

抗瓜氨酸化肽抗体与早期类风湿关节炎临床及影像学结局相关:前瞻性起始队列研究

Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study.
PubMed 文献 · RMD Open · 2019-09-03

该前瞻性起始队列纳入1022例症状<12个月的早期类风湿关节炎患者,用定制微阵列芯片检测22种瓜氨酸化肽的ACPA反应性,并随访24个月评估DAS28及影像学。结果显示不同ACPA反应性频率为13.3%-63.1%,部分抗体可预测DAS28轨迹及Larsen评分与影像学进展。

要点

  • 抗CCP2阴性患者中32.6%仍存在ACPA反应性。
  • 抗Fibβ62-78(74)和抗Fibα563-583阳性预测更高DAS28。
  • 抗波形蛋白2-17抗体与基线及24个月Larsen评分和影像学进展相关。

核心结论

  • 多种ACPA反应性显著改变早期RA患者24个月内DAS28的发展轨迹。
  • 部分ACPA反应性与基线、24个月Larsen评分及影像学进展显著相关。

研究设计与样本

  • 前瞻性起始队列研究,纳入1022例症状<12个月的早期RA患者。
  • 使用定制微阵列芯片检测22种瓜氨酸化肽的ACPA反应性,随访24个月观察DAS28及影像学。

主要发现

  • ACPA反应性频率在13.3%至63.1%之间。
  • 抗CCP2抗体阴性患者中ACPA反应性阳性率为32.6%。
  • 吸烟、HLA-SE、抗CCP2/类风湿因子、PTPN22(1858C/T)及DAS28与ACPA反应性数量显著相关。
  • 抗Filaggrin307-324、抗hnRNP(Peptide)-Z1和抗F4-CIT-R抗体预测较低DAS28值(p<0.01-0.05)。
  • 抗Fibβ62-78(74)和抗Fibα563-583阳性预测较高DAS28(p<0.01)。

关键数值与推荐

  • 抗Fibβ62-78(74)和抗Fibα563-583阳性预测较高DAS28(p<0.01)。
  • 抗Filaggrin307-324、抗hnRNP(Peptide)-Z1和抗F4-CIT-R抗体预测较低DAS28(p<0.01-0.05)。
  • 抗Fibβ36-52、抗Pept-5和抗Bla-26抗体与24个月DAS28交互作用显著降低DAS28值(p<0.01-0.05)。
  • 抗波形蛋白2-17抗体与基线及24个月Larsen评分和影像学进展显著相关。

临床怎么用

  • 在早期RA中检测多种ACPA反应性可能有助于识别不同临床和影像学结局风险的患者。
  • 抗CCP2阴性患者仍应关注ACPA反应性以评估疾病活动性和影像学进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Anticitrullinated peptide antibody (ACPA) responses for 22 citrullinated peptides in patients with early rheumatoid arthritis (RA) were analysed and related to radiological and clinical outcome during the first 2 years in a prospective inception cohort. METHODS: The ACPA reactivities were assessed in 1022 patients with early RA (symptoms <12 months) using the custom-made microarray chip (Thermo Fisher Scientific, Uppsala, Sweden) in a prospective longitudinal study of observational assessments of Disease Activity Score (DAS28 and its components) and radiology during the first 24 months, accounting for the treatment. RESULTS: Frequency of ACPA reactivities varied between 13.3% and 63.1%. Of the anticyclic citrullinated peptide-2 (anti-CCP2) antibody-negative patients, ACPA reactivities were positive in 32.6%. Smoking, human leucocyte antigen-shared epitope (HLA-SE), anti-CCP2/rheumatoid factor, protein tyrosine phosphatase non-receptor type 22 (1858C/T) and DAS28 were significantly associated with number of ACPA reactivities. The ACPA reactivities modified differently the development of DAS28 over 24 months (identified using trajectories). Anti-Filaggrin307-324, anti-hnRNP (Peptide)-Z1 and anti-F4-CIT-R antibodies anticipated lower DAS28 values (p<0.01-0.05), while positivity for anti-Fibrinogen(Fib)β62-78(74), and anti-Fibα563-583 predicted higher DAS28 (p<0.01 both). Interaction between anti-Fibß36-52, anti-Pept-5 and anti-Bla-26 antibodies, respectively, and DAS28 during 24 months decreased significantly the DAS28 values (p<0.01-0.05). Corticosteroids and biologicals were related to DAS28-area under the curve and Larsen score 24 months. Anti-vimentin2-17 antibodies remained significantly associated with Larsen score at baseline and 24 months, respectively, and radiological progression, besides biologicals at 24 months adjusted for sex and age. CONCLUSIONS: Several ACPA reactivities modified significantly the DAS28 development during the first 24 months and were significantly associated with Larsen score at baseline, 24 months and radiological progression.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Boman A, Brink M, Lundquist A, et al. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study. RMD Open. 2019. PMID: 31565241. doi:10.1136/rmdopen-2019-000946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。